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We have developed two monoclonal antibodies to human lipocortin-1 (103 and 105) as reagents for quantitating the protein in biological systems 
and neutralizing its activity. Lipo 105 is a high affinity antibody that is functional in ELISA and Western blot formats. The antibody recognizes 
a site between amino acids 30 and 55 in the lipocortin-I sequence and can be used on native or denatured protein. Lipo 103 is an antibody that 
neutralizes the phospholipase A, inhibitory activity of lipocortin-1 by blocking binding of the protein to phospholipid surfaces. The antibody is 
specific for native human lipocortin-1. Lipo 103 was recently shown to block lipocortin-l-dependent differentiation of a squamous carcinoma cell 
line, demonstrating its usefulness as a probe for function. 
Lipocortin; Annexin; Phospholipid binding protein; Caz+ dependent 
1. INTRODUCTION 
The lipocortins or annexins are a family of calcium 
and phospholipid binding proteins that have been im- 
plicated in diverse processes, ranging from intracellular 
events where they have been postulated to play roles in 
membrane-cytoskeleton interactions and signal 
transduction to extracellular events where they affect 
inflammation, blood coagulation, the immune 
response, growth and differentiation (see [l] for refs). 
Seven distinct proteins have been characterized to date, 
all sharing approx. 50% sequence identity (see [2,3] for 
refs). Most conserved is a 70 amino acid repeat unit 
that is responsible for calcium and phospholipid bin- 
ding. The 35-45 kDa Iipocortins contain 4 copies of 
the unit and the 70 kDa lipocortins, 8 copies. Distinct 
from the repeat units is a short amino-terminal segment 
that is unique to each protein. Although the repeat 
units bind,,/caIcium and phospholipid, the amino- 
terminal/ segment regulates the binding affinities and 
thus is likely to provide specificity to the different fami- 
ly members 14-61. Lipocortin-like proteins have been 
purified from a variety of systems. Other names for 
these related proteins include ~hromobindins, calpac- 
tins, calelectrins, cal~imedins, endonexins, placenta 
anticoagulant proteins, and proteins I-III (see [7,8] for 
reviews). 
Furthermore the mechanism of action is unknown. To 
better evaluate the biological functions of lipocortin-1 
we have produced a panel of monoclonal antibodies, 
screening in particular for antibodies that could block 
activity. Here we describe the properties of a neutraliz- 
ing antibody, which functions by blocking the associa- 
tion of lipocortin with membranes. Because of its 
specificity, the antibody should serve as a valuable 
reagent for studying the function of Iipocortin-1. 
2. MATERIALS AND METHODS 
2.1. Purificatioi of l~~~o~t~~-like proteins 
R~ombinant human lipocortin-1 was produced in E. co/i [9]. “S- 
labeled lipocortin-1 was produced in the same strain, using cells that 
were adapted to grow in low sulphate medium. A 50 ml culture was 
grown in the presence of 10 mCi [“S]sulphate and labeled lipocortin 
purified as previously described [17,18]. Human, rat, and bovine 
lipocortins l-6 were purified as described [1,2]. 
2.2. Production of monoclonal antibodies 
Lipocortin-I, as the first member of the family to 
have been cloned and expressed [9], has become the 
prototype of the group. The recombinant protein has 
been tested in a variety of systems and shown to display 
diverse activities [lo-161; however, it remains unclear 
which of these activities are physiologically relevant, 
BALB/c mice (female, 4-6 weeks) were immunized with an in- 
traperitoneal injection (10 &mouse) of recombinant lipocortin-1 in 
complete Freund’s adjuvant. The animals were boosted on days 14 
and 28 with lipocortin-1 (10 pg/mouse) in incomplete Freund’s adju- 
vant. After 6 weeks, test bleeds were taken and screened for an- 
tibodies that blocked lipocortin-1 activity in the phosphoIipase Az 
inhibition assay. Antisera from 2 of 6 mice displayed anti-lipocort~n 
activity. Four days prior to the fusion, both animals were boosted 
with intravenous injections containing 20pg of lipocortin. The 
animals were sacrificed and the spleen cells fused with SP3 x Ag8 cells 
for hybridoma production [19]. 
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Hybridoma culture supernatants were assayed for antibodies that 
could precipitate radiolabeled lipocortin-1. 20000 cpm of “S-labeled 
lipocortin was mixed with 50~1 of conditioned medium from each 
clone and incubated for 1 h at 4’C. Mouse IgG and goat anti-mouse 
IgG preparations were added and samples further incubated for 2 h 
at 4°C. The immune complexes were pelleted, washed with PBS, 
dissolved in 0.1 N NaOH and quantitated by scintillation counting. 
Hybridomas producing antibodies that precipitated over 50% of the 
input counts were subcloned by limiting dilution. The 5 most promis- 
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ing lines (lip0 101-105) were grown as ascites in pristane-primed 
mice. The monoclonal antibodies were affinity-purified on protein A 
Sepharose, using the Pierce binding and elution buffer systems. Lipo 
101-104 were isotyped as IgGi and lipo 105, as Ig&. 
2.3. Western blotting 
Lipocortin-1 and its cleavage products were analyzed by SDS- 
PAGE [l]. Proteins were either stained directly with Coomassie 
brilliant blue R-250 or subjected to Western analysis. For Western 
blots, proteins were transferred to nitrocellulose and probed with 
monoclonal antibodies at 10 &g/ml or with rabbit antisera to recom- 
binant lipocortin (no.646) diluted at 1: 1000. Immunoreactive bands 
were visualized with goat anti-mouse or goat anti-rabbit IgG-HRP 
conjugates as appropriate. 
CNBr fragments of lipocortin-1 were generated under limiting con- 
ditions. Immunoreactive fragments were either directly probed with 
lipo 101-105 on Western blots [l] or precipitated with the 
monoclonal antibodies and the complexes blotted and probed with 
the 646 antiserum. In the latter case, lipocortin was treated with 
CNBr in 70% formic acid for 1 h at 23’C, lyophilized, and the diges- 
tion products renatured [IS]. Fragments were diluted with 10 vols of 
lysis buffer [17] and incubated for 1 h at 4°C with a 5-fold molar ex- 
cess of monoclonal antibody. The immune complexes were collected 
on goat anti-mouse IgG Sepharose, disrupted with etectrophoresis 
sample buffer, and subjected to Western analysis. 
2.4. ~hospholip~e A2 ~nh~bi~~o~ assay 
Antibodies were tested for their effect on Iipocortin activity in a 
phospholipase AZ assay, using [3H]oleic acid-labeled E. cob’ as 
substrate [I]. Lipocortins were incubated with antibody for 1 h at 
4”C, then mixed with phospholipase A2 and with labeled E. coli and 
incubated at 8°C for 6 min. Reactions were quenched with HCI and 
activity assessed by monitoring released [3H]oleic acid from the label- 
ed substrate by scintillation counting. 
2.5. Binding of lipocortin-I to formalin-fixed bacteria 
Recombinant human lipocortin-1 (5 pg/tube) was mixed with 
O-100 pg of the 103 antibody in 100 ~1 of 25 mM ‘Iris-HCl, pH 7.7, 
0.1 mglml BSA, 8 mM CaC12 and incubated at 4°C for 1 h. 8 ~1 of 
formalin-axed E. coii (see below) was added and the samples in- 
cubated on ice for 1 h. The bacteria were pelleted in an Ep~ndorf 
centrifuge (1 min, 10000 rpm) and the supernatants transferred to 
fresh tubes. Supernatants were treated with 25 pl of 5 x eiec- 
trophoresis sample buffer and the pellets, with 125 pl of 1 x sample 
buffer. Both sets of samples were heated at 65°C for 10 min and 15 pl 
aliquots analyzed by SDS-PAGE, Formalinfixed E. coli [20] were 
stored at -20°C as a 20% solution in PBS, 0.02% NaNj. Immediate- 
ly prior to their use, the bacteria were washed with 25 mM Tris-HCl, 
pH 7.7, and then diluted 6-fold with the same buffer. 
2.6. ELBA anaiysis 
Immulon-2 plates (Dynatech) were coated overnight at 4°C with 
lO,~g/mi antibody in 50 mM NasC03, pH 9.6. Wells were blocked 
with 1% fetal bovine serum in the same buffer. Plates were treated 
with serial dilutions of lipocortin in SO mM Tris-HCl, pH 7&O. 1 M 
NaCl, 1 mM EDTA, 0.05% Tween-20, 1% fetal bovine serum for 3 h 
at 23°C then with a 1 : lOGO dilution of anti-human lipocortin-1 an- 
tiserum (rabbit no.842) for 2 h at 23%. and finaIly with a 1: lOCOO 
of goat anti-rabbit IgG-HRP conjugate (Cappel) for 1 h at 23°C. 
Plates were developed with tetramethyl benzidine color reagent. 
100 ~1 vols were used for all additions. Between steps, plates were 
washed 3 times with PBS containing 0.05% Tween-20. 
3. RESULTS 
Recombinant human lipocortin-1 was used as an im- 
munogen in the production of monoclonal antibodies 
in BALB/c mice. Hybridoma supernatants were screen- 
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ed for antibodies that recognized radiolabeled 
lipocortin-1 by immune precipitation, insuring that all 
of the antibodies selected recognized protein in a native 
conformation. Five monoclonal antibodies were 
generated and designated lipo 1 Ol- 105. Subsequently, 
the antibodies were checked by ELISA, Western blot- 
ting, and for their ability to block lipocortin activity in 
a phospholipase AZ assay. Although no single antibody 
covered all the desired applications, two of the an- 
tibodies together were useful in this respect, providing 
a set of reagents for qu~titating lipocortin-1 and for 
neutralizing its activity. 
Fig.1 shows results from Western blots where recom- 
binant and natural preparations of lipocortin-1 were 
electrophoretically transferred to nitrocellulose and 
then probed with culture medium from the various 
hybridoma lines. 2 of the 5 antibodies - lipo 102 and 
105 - detected the denatured lipocortin. In the natural 
preparation a small portion of the product was pro- 
teolytically clipped near its N-terminus forming a 
des30 adduct. Both antibodies recognized the trun- 







Fig. 1. Western blot analysis of lipocortin-1 monoclonal antibodies. 
Recombinant (top panel) and natural (bottom panel) preparations of 
human lipocortin-1 (100 ng/track) were subjected to SDS-PAGE, 
transferred to nitroceliulose, and probed with conditioned medium 
from the lipo 101-105 hybridoma cell lines (lanes c-g, respectively). 
Control medium (lane a) and immune serum from one of the mice 
used for antibody production (lane b) are presented as negative and 
positive controls. Ll denotes the position of lipocortin-1. 
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Fig.2. CNBr mapping of immunoreactive fragments. CNBr 
fragments of lipocortin-1 were separated on SDS-gels, transferred to 
nitrocellulose, and probed either with lipo 105 antibody (lane a), with 
rabbit antiserum to lipocortin-1 (lane b), or immune-precipitated 
with lipo 105 antibody, and these fragments detected on Western 
blots with the ~ti-Ii~co~n-1 rabbit antiserum (lanes c-f). 
Lipocortin in lanes c-f was treated with 0, 7, 14 and 21 mg/ml 
CNBr. Lanes l-4, 8 and T show schematic diagrams summarizing 
the CNBr mapping data [21] where l-4, and 8 represent profiles for 
specific fragments and T represents the total digest. Numbers at the 
right denote fragment compositions where 1 refers to the N-terminal 
CNBr fragment and 8 to the C-terminal fragment. 
reactive than lipo 105. In fig. 1, the 35 kDa fragment is 
barely detected with the 102 antibody. 
The reactive epitopes for the IO2 and 105 antibodies 
were further localized by CNBr mapping (see fig.2). 
CNBr cleaves lipocortin- 1 into 8 fragments with masses 
of: 6.2, 7.8, 13.3, 4.2, 1.5, 0.9, 1.1 and 3.1 kDa from 
N- to C-terminus, respectively. By analyzing partial 
CNBr digests in a nearest neighbor-type analysis, each 
complete CNBr fragment is represented by a distinct 
subset of the cleavage products. When CNBr cleavage 
products were probed with lipo 102 and 105, a series of 
5 fragments were detected that were identical for the 
two monoclonals (only the lipo-105 map is presented). 
Of the 23 known cleavage products in the cleavage map 
of lipocortin-1 [21], only the 5 fragment-l-containing 
cleavage products were observed, indicating that the 
reactive epitope is associated with CNBr fragment-l. In 
conjunction with results for the des-30 variant, the 
mapping analysis localized the reactive epitope between 
amino acids 30-55 in the lipocortin-1 sequence. 
Attempts to define the binding sites for the 101, 103 
and 104 antibodies were unsuccessful. In addition to 
direct and indirect analyses of fragments by CNBr 
mapping (fig.2), we tried to localize the epitope by 
cleaving lipocortin with elastase under limiting condi- 
tions [18] and then using the antibodies to immune- 
precipitate functional fragments. None of the 
fragments were detected. We also attempted various 
cross-linking approaches where lipoco~in-antibody 
complexes were fixed with chemical cross-linkers, SDS- 
gel purified, and analyzed by CNBr mapping [22]. Ex- 
tensive cross-linking was observed with N-5-azido-2- 
nitrobe~oyloxysuccimide and with ~-~idophenyl 
glyoxal and minimal cross-linking, with dimethyl 
suberimidate, difluorodinitrobenzene and ethylene 
glycol-bis(succimidyl-succinate). Peptide maps of the 
covalent lipocortin-antibody complexes failed to 
localize the binding sites (data not shown). 
Since the primary goal for producing monoclonals 
was to obtain antibodies that could be used as probes 
for investigating the biology of lipocortin-1, lipo 
101-105 were screened for their effects on lipocortin 
activity towards phospholipase AZ. While the 
rn~h~isrn of phospholipase inhibition does not in- 
volve a direct enzyme-inhibitor interaction, the role of 
this pathway has been supported in various recent 
studies [lo- 12,161. When conditioned medium from 
lipo 101-105 hybridomas were tested for anti-lipocor- 
tin-l activity, lipo 103 and 105 showed blocking activi- 
ty. In a more qu~titative analysis of the i~ibition 
using affinity-purified antibody, only the lipo 103 an- 
tibody showed significant blocking activity (see fig.3) 
and thus most subsequent studies focused on char- 
acterizing lip0 103. 
To better understand the mechanism of inhibition, a 
simple membrane binding system was used where bin- 
ding of lipocortin-1 to bacterial membranes could be 
monitored in the same format as binding occurs in the 
phospholipase assay. When lipocortin was incubated 
with varying concentrations of lipo 103 antibody and 
I 
0 
N 20 i \ 
Fig.3. Dose-response curves of anti-lipocortin activity. Affinity 
purified lipo 103 and 105 antibodies were incubated with lipocortin-1 
and then assayed for phospholipase inhibitory activity. Numbers 
presented represent residual phosphofip~e inhibitory activity 
remaining after ~tib~y treatment. (D---=) Lipo 105; (O---O) lipo 
103. 
249 
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the membrane binding of lipocortin assessed on SDS- 
gels, we obtained the results shown in fig.4. In the 
absence of antibody, all of the lipocortin was 
associated with the bacteria whereas the presence of an- 
tibody led to a dose-dependent inhibition of lipocortin 
binding. Near stoichiometric concentrations of an- 
tibody blocked membrane binding. Since membrane 
binding is a prerequisite for phospholipase inhibition, 
this result suggests that the inhibition of lipocortin ac- 
tivity results from blocking its binding to membranes. 
Interestingly, in the lipocortin-I preparation used in the 
membrane binding assay, about 20% of the protein ex- 
isted as a des-30 fragment. The ability of lipo 103 to 
recognize the truncated variant indicates that the 
epitope for the antibody lies within the core structure 
of lipocortin. 
Since lipocortins are a family of proteins that share 
extensive sequence homology, ranging from 40-60% 
identity among the various members, the specificity of 
the antibody was an important consideration. Table 1 
summarizes results where human lipocortins l-6 were 
assayed for brass-reactivity with the lipo 103 antibody 
by testing for blocking activity in the phospholipase AZ 
assay. Only lipocortin-1 activity was affected by the an- 
tibody, indicating a high degree of specificity for the 
antibody. No cross-reactivity was seen towards bovine 
lipocortins 2-6 as well, supporting its specificity (data 
not shown). Finally, we tested the lipo 103 antibody for 
potential cross-reactivity with rat lipocortin-1 , which 
shares 85% identity with the human protein. The rat 
lipocortin was not inhibited by the 103 antibody. 
Although the association of lipo 103 with lipocortin 
is readily detected in solution, there was no apparent 
binding when lipocortin was coated on plastic or bound 
to cell surfaces and then probed for binding. When 
lipocortin-coated immulon-2 plates were incubated 
with lipo 103 and 105 antibodies and binding assessed 
using a goat anti-mouse IgG-HRP reporter system, we 
observed a typical dose-response with an IDso for lip0 
105 of 15 ng antibody/ml. In contrast, the apparent 
Table 1 
Specificity of the lipo 103 antibody towards human lipocortins 
Lipocortin species Percent inhibition 
-103 ii03 
1 88 25 
2 89 90 
3 87 91 
4 98 96 
5 91 98 
6 84 82 
Human lipocortins 1-6 (1 pg each) were incubated with or without 
lop8 of affinity-purified 103 antibody and then assayed for 
phospholipase AZ inhibitory activity. Numbers presented represent 
residual phospholipase inhibitory activity remaining after antibody 
treatment 
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Fig.4. The 103 antibody blocks lipocortin-I from binding to 
membranes. The binding of lipocortin to formalin-fixed bacteria was 
evaluated in the presence and absence of the lipo 103 antibody. Each 
sample was split into bound (pellet) and unbound (su~rnat~t) 
fractions and then subjected to SDS-PAGE. Proteins were stained 
with Coomassie blue. (Lane a) BRL prestained high molecular weight 
markers; (lane b) O.Sag of recombinant lipocortin-I; (lanes c-h) 
supernatant and pellet fractions from samples that had received 0, 
0.5, 1, 2.5, 10 and I5 pg of antibody, respectively. 
titer for the lipo 103 antibody was less than one- 
thousandth of what the 105 antibody produced in the 
same format. Similar differences were obtained when 
recombinant lipocortin was bound to cell surfaces and 
quantitated using fluorescence activated cell sorting. 
Surface-bound lipoco~in was readily detected with the 
lipo 105 antibody, but absent in a parallel analysis run 
with lipo IO3 antibody (Browning, J., unpublished). 
Fig.5 shows a direct comparison of the two antibodies 
in a sandwich ELISA. While both antibodies detect 
lipocortin in this format, lipo 105 is 10 times as sen- 
sitive as lipo 103 and provides a simple method for 
quantitating ng amounts of the protein. 
4. DISCUSSION 
We have characterized two monoclonal antibodies, 
lipo 103 and 105, as reagents that can be used to study 
the biology of lipocortin-1. Lipo 103 (which we now 
refer to as 1A) is of interest as a neutraiizing antibody. 
In addition to blocking lipocortin-1 activity in 
phospholipase AZ assays, the antibody recently was 
shown to block activity in a lipocortin-l-dependent cell 
differentiation assay [ 151 and thus hould be a useful 
tool for functional studies involving lipocortin-1. The 
105 antibody (which we now refer to as 1B) provides a 
simple method for quantitating lipocortin-1. The an- 
tibody has proven to be useful for evaluating 
lipocortin-1 in human clinical samples in a sandwich 
ELISA format and for detecting surface-bound 










Fig.% A sandwich ELISA for quantitating lipocortin-1. Immulon-2 
plates coated with lipo 103, 105, or control mouse IgG were treated 
with serial dilutions of lip~ortin, then with rabbit anti-lipo~o~in-1 
antiserum, and finally with goat anti-rabbit IgG-HRP conjugate. 
Signals were quantitated spectrophotometrically at 450 nm with a 
Dynatech microplate reader. (a---m) Lipo 105; (o---o) lipo 103; 
(O---O) control Ig%. 
lipocortin. The epitope for the 105 antibody is localized 
within a segment between amino acids 30 and 55 in the 
lipocortin-1 sequence. The Iipo 105 antibody recogniz- 
ed rat lipocortin-1 on Western blots and thus hould be 
useful for evaluating lipocortin-1 levels in animal 
models. 
The specificity and mode of action of the 103 an- 
tibody are of special interest because of the potential 
applications of the antibody as a probe for function. 
Out of the 6 lipocortins that we have characterized [2], 
only lipocortin-1 was neutralized by lipo 103, indicating 
that the antibody is a specific reagent. Rat lipocortin-1, 
which shares 85% identity with the human protein, was 
not blocked by the antibody further supporting this no- 
tion. Although we were unable to precisely define the 
reactive epitope, the antibody recognized the truncated 
des30 variant and thus interacts with the core structure 
of lipocortin, which contains the calcium and 
phospholipid binding domain. Since many of the ac- 
tivities of lipocortin-like proteins result from mem- 
brane binding, we tested whether the antisera might 
affect this property. In a simple assay using formalin- 
fixed bacteria as a surface for monitoring binding, we 
have demonstrated that the antibody blocks lipocortin 
binding to membrane, indicating its likely site of 
action. 
The complexity of the lipocortins in the number of 
proteins alone has created confusion in understanding 
the biological sig~fic~ce of any one family member. 
Interestingly, in those cases where the proteins have 
been localized by immunohistochemical techniques, 
they exhibit distinctive cellular distributions [23,24], in- 
dicating specialized roles. Neutralizing antibodies pro- 
vide a simple method for probing function, by allowing 
one to inactivate existing protein and test the effect of 
the perturbation on the system. Historically 3 different 
neutralizing antibodies to lipocortin-like proteins have 
been used in various systems. All were prepared with 
ill-defined immunogens. Fu~hermore, none of these 
antibodies were characterized for specificity or mode,of 
action and thus they have not been widely used 
[25-271. The 1A antibody is unique in that it represents 
the first reagent for which specificity and mechanism 
are known. 
Recently several groups have produced monoclonal 
antibodies against specific lipocortins [5,28]. To date 
little is known about heir properties or applications. 
Furthermore, none of the antibodies were developed as 
neutralizing reagents. In the extensive study by Glenney 
and Zokas [5], 13 monoclon~s to lipocortin-1 were 
produced and characterized with respect to potential 
uses for studying actin binding, phosphorylation by the 
EGF receptor, and binding to phosphatidyl serine 
vesicles. All 13 antibodies worked on Western blots and 
9 were found to recognize the amino-terminal tail 
region. In our panel of antibodies, only two of the an- 
tibodies work on Western blots and none recognized 
the tail region, indicating that the screen we adopted 
yielded a distinctive set of antibodies. While further 
studies are needed to better define the applications of 
the 103 and 105 antibodies, initial studies 115,291 in- 
dicate that they should serve as valuable tools for quan- 
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